临床研究视角下的SGLT2抑制剂:糖尿病心力衰竭治疗的“破界先锋”

陈玲 ,  王中群

中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (6) : 722 -728.

PDF (743KB)
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (6) : 722 -728. DOI: 10.12092/j.issn.1009-2501.2026.06.001

临床研究视角下的SGLT2抑制剂:糖尿病心力衰竭治疗的“破界先锋”

作者信息 +

SGLT2 inhibitor from a clinical research perspective: boundary-break- ing pioneer in the treatment of diabetic heart failure

Author information +
文章历史 +
PDF (760K)

摘要

大量的临床试验证实,使用钠-葡萄糖协同 转运蛋白 2 抑制剂 (sodium- glucose co-trans- porter 2 inhibitor,SGLT2i)治疗可显著降低糖尿 病患者的心力衰竭(heart failure,HF)发生风险,并改善已合并HF患者的临床结局。本综述基于循证医学,总结目前对支持糖尿病 HF 患者 使用 SGLT2i 临床获益的理解和证据,为糖尿病 HF 的临床用药提供新策略和依据。

Abstract

Extensive clinical trials have demonstrated that treatment with sodium-glucose co- transporter 2 inhibitor (SGLT2i) significantly re- duces the risk of heart failure (HF) in patients with diabetes and improves clinical outcomes in those with established HF. Grounded in evidence-based medicine, this review summarizes current under- standing and supporting evidence for the clinical benefits of SGLT2i in diabetic HF, providing new therapeutic strategies and rationale for its manage- ment.

关键词

心力衰竭 / 糖尿病 / SGLT2 抑制剂

Key words

heart failure / diabetes / sodium-glu- cose co-transporter 2 inhibitors

引用本文

引用格式 ▾
陈玲,王中群. 临床研究视角下的SGLT2抑制剂:糖尿病心力衰竭治疗的“破界先锋”[J]. 中国临床药理学与治疗学, 2026, 31(6): 722-728 DOI:10.12092/j.issn.1009-2501.2026.06.001

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

Pandey A, Khan MS, Patel KV, et al. Predicting and pre- venting heart failure in type 2 diabetes[J].Lancet Diab Endocrinol, 2023, 11(8): 607-624.

[2]

Pop-Busui R, Januzzi JL, Bruemmer D, et al. Heart fail- ure: an underappreciated complication of diabetes. A consensus report of the American diabetes association[J].Diabetes Care, 2022, 45(7): 1670-1690.

[3]

Khan MS, Shahid I, Bennis A, et al. Global epidemiolo- gy of heart failure[J].Nat Rev Cardiol, 2024, 21(10): 717-734.

[4]

Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the european association for the study of diabetes (EASD)[J].Diabetes Care, 2022, 45(11): 2753-2786.

[5]

Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 dia- betes mellitus and heart failure: ascientific statement from the American heart association and the heart fail- ure society of america: this statement does not repre- sent an update of the 2017 ACC/AHA/HFSA heart fail- ure guideline update[J].Circulation, 2019, 140(7): 311-318.

[6]

Preda A, Montecucco F, Carbone F, et al. SGLT2 in- hibitors: from glucose-lowering to cardiovascular bene- fits[J].Cardiovas Res, 2024, 120(5): 443-460.

[7]

Bonaventura A, Carbone S, Dixon DL, et al. Pharmaco- logic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT -2 inhibitors and GLP -1 receptor agonists[J].J Intern Med, 2019, 286(1): 16-31.

[8]

Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 dia- betes[J].N Engl J Med, 2015, 373(22): 2117-2128.

[9]

Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes[J].N Engl J Med, 2017, 377(7): 644-657.

[10]

Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes[J].N Engl J Med, 2019, 380(4): 347-357.

[11]

Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovas- cular outcomes with ertugliflozin in type 2 diabetes[J].N Engl J Med, 2020, 383(15): 1425-1435.

[12]

Rao S. Use of sodium-glucose cotransporter-2 in- hibitors in clinical practice for heart failure prevention and treatment: Beyond type 2 diabetes. A narrative re- view[J].Adv Ther, 2022, 39(2): 845-861.

[13]

Greene SJ, Butler J, Kosiborod MN.Chapter 3: clinical trials of sodium-glucose co-transporter-2 inhibitors for treatment of heart failure[J].Am J Med, 2024, 137(2): S25-S34.

[14]

Khunti K,Kosiborod M,Kim DJ,et al. Cardiovascular outcomes with sodium-glucose cotransporter-2 in- hibitors vs other glucose-lowering drugs in 13 coun- tries across three continents: Analysis of CVD-REAL da- ta[J].Cardiovasc Diabetol, 2021, 20(1): 159.

[15]

McMurray JJV, Solomon SD, Inzucchi SE, et al. Da- pagliflozin in patients with heart failure and reduced ejection fraction[J].N Engl J Med, 2019, 381(21): 1995-2008.

[16]

Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure[J].N Engl J Med, 2020, 383(15): 1413-1424.

[17]

Szarek M, Bhatt DL, Steg PhG, et al. Effect of so- tagliflozin on total hospitalizations in patients with type 2 diabetes and worsening heart failure: a random- ized trial[J].Ann Intern Med, 2021, 174(8): 1065-1072.

[18]

Anker SD, Butler J, Filippatos G, et al. et al. Empagliflozin in heart failure with a preserved ejection fraction[J].N Engl J Med, 2021, 385(16): 1451-1461.

[19]

Solomon SD, McMurray JJV, Claggett B, et al. Da- pagliflozin in heart failure with mildly reduced or pre- served ejection fraction[J].N Engl J Med, 2022, 387(12): 1089-1098.

[20]

Bhatt AS, Kosiborod MN, Vaduganathan M, et al. Ef- fect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: participant - level pooled analysis from the DAPA-HF and DELIVER trials[J].Eur J Heart Fail, 2023, 25(7): 981-988.

[21]

Beghini A, Sammartino AM, Papp Z, et al. 2024 update in heart failure[J].ESC Heart Failure, 2025, 12(1): 8-42.

[22]

Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American college of cardiology/american heart association joint commit- tee on clinical practice guidelines[J].Circulation, 2022, 145(18): e895-e1032.

[23]

McDonagh TA, Metra M, Adamo M, et al. et al. 2023 fo- cused update of the 2021 ESC guidelines for the diag- nosis and treatment of acute and chronic heart failure[J].Eur Heart J, 2023, 44(37): 3627-3639.

[24]

Schupp T, Bertsch T, Reinhardt M, et al. Effect of heart failure pharmacotherapies in patients with heart fail- ure with mildly reduced ejection fraction[J].Eur J Prev Cardiol, 2024, 31(11): 1347-1360.

[25]

Vaduganathan M, Claggett BL, Inciardi RM, et al. Esti- mating the benefits of combination medical therapy in heart failure with mildly reduced and preserved ejec- tion fraction[J].Circulation, 2022, 145(23): 1741-1743.

[26]

Zafeiropoulos S, Farmakis IT, Milioglou I, et al. Pharma- cological treatments in heart failure with mildly re- duced and preserved ejection fraction[J].JACC: Heart Failure, 2024, 12(4): 616-627.

[27]

中国医师协会心血管内科医师分会, 中国心衰中心 联盟, 《慢性心力衰竭"新四联"药物治疗临床决策路 径专家共识》工作组. 慢性心力衰竭"新四联"药物治 疗临床决策路径专家共识[J].中国循环杂志, 2022, 37(8): 769-781.

基金资助

江苏省科技厅重点研发项目(BE2022780)

AI Summary AI Mindmap
PDF (743KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉